Cargando…
Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy
OBJECTIVES: The fact that studies on anti‐programmed cell death 1 (PD‐1) or its relevant ligand 1 (PD‐L1) have yielded such few responses greatly decreases the confidence in immunotherapy with checkpoint inhibitors for advanced osteosarcoma. We intended to characterize the expression of various chec...
Autores principales: | Xie, Lu, Chen, Chenglong, Liang, Xin, Xu, Jie, Sun, Xin, Sun, Kunkun, Yang, Rongli, Tang, Xiaodong, Guo, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977595/ https://www.ncbi.nlm.nih.gov/pubmed/36519392 http://dx.doi.org/10.1111/os.13620 |
Ejemplares similares
-
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2020) -
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020) -
Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023) -
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022) -
Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
por: Meftahpour, Vafa, et al.
Publicado: (2022)